Shennon Biotechnologies
Shennon Biotechnologies is developing precision T-cell engager immunotherapies for solid tumors.
$12MFunding
ParticipantAV
AV8 Ventures
Activity from announced rounds
Activity in this selectionUndisclosed
AV8 Ventures is an investment firm with recorded relationships to Think Bioscience and Shennon Biotechnologies.
Recorded funding activity
Think Bioscience develops small-molecule medicines for historically difficult drug targets. Shennon develops precision T-cell engager immunotherapies for solid tumors. The two financing histories connect the firm to different drug-development approaches without establishing a complete sector or portfolio allocation.
Sources
- Rounds participated in
- 1
- Confirmed lead rounds
- 0 All roles disclosed
- New companies
- 1 First participation on record · 0 follow-on
- Funding in participating rounds
- $12M 1 disclosed · full round size, not this investor’s share